BioCentury
ARTICLE | Company News

Elan, Isis deal

June 14, 2004 7:00 AM UTC

ISIS will acquire ELN's minority interest in JVs Orasense and HepaSense. As a result of the deal, ISIS will no longer owe ELN royalties related to the oral delivery platform developed by the Orasense ...